AtriCure (ATRC) vs Warby Parker (WRBY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AtriCure (ATRC) has outperformed Warby Parker (WRBY) over the past year, gaining 53.0% versus a gain of 6.6%. Over five years, ATRC leads with a -26.0% price change compared with -54.4% for WRBY. Warby Parker is the larger company by market cap ($3.13 billion vs $2.84 billion), about 1.1 times the size, while AtriCure is growing revenue faster (+14.9% vs +13.0%).
On valuation, Warby Parker trades at a lower forward P/E (41.2x vs 128.6x for AtriCure). Warby Parker converts more of its revenue into profit, with a net margin of 0.2% versus -2.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRC | WRBY |
|---|---|---|
| Share price | $55.81 | $25.30 |
| Market cap | $2.84B | $3.13B |
| 1-day change | +5.62% | +1.40% |
| YTD return | +41.08% | +16.11% |
| 1-year return | +53.03% | +6.57% |
| 5-year return | -25.96% | -54.43% |
| P/E ratio (TTM) | 265.76 | 421.67 |
| Forward P/E | 128.60 | 41.15 |
| EPS (TTM) | $0.21 | $0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $534.53M | $871.90M |
| Revenue growth (YoY) | +14.88% | +13.04% |
| Net income (latest FY) | $-11.45M | $1.64M |
| Gross margin | 74.98% | 53.97% |
| Operating margin | -1.77% | -0.61% |
| Net margin | -2.14% | 0.19% |
| 52-week high | $61.70 | $31.00 |
| 52-week low | $25.36 | $14.96 |
| Distance from 52-week high | -9.55% | -18.39% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -1.65% | +20.40% |
| Average volume | 1.09M | 2.87M |
| Shares outstanding | 50.87M | 108.24M |
| Employees | 1,350 | 2,275 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Ophthalmic Goods |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRC has outperformed WRBY by 46.5 percentage points over the past year.
- Warby Parker trades at a higher earnings multiple (421.7x vs 265.8x trailing P/E).
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Health Care · Medical/Dental Instruments · 1,350 employees
About Warby Parker
WRBY stock →Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada.
Health Care · Ophthalmic Goods · 2,275 employees
ATRC vs WRBY FAQ
Which is bigger, AtriCure or Warby Parker?
Warby Parker (WRBY) is larger, with a market capitalization of $3.13B compared with $2.84B for AtriCure (ATRC).
Which stock has performed better over the past year, ATRC or WRBY?
ATRC returned +53.03% over the past 12 months, compared with +6.57% for WRBY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ATRC or WRBY?
ATRC has the lower trailing P/E at 265.8, versus 421.7 for WRBY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AtriCure and Warby Parker in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for AtriCure and Ophthalmic Goods for Warby Parker.